The Clinical Study of Comorbidities and Systemic Inflammation in COPD
Abstract
To assess the association between chronic obstructive pulmonary disease (COPD) comorbidities and clinical characteristics, and to explore the inflammation mechanism. Methods 220 stable COPD patients were included. Clinical characteristics and comorbidities were recorded, and blood samples were collected. The relationship among the number and type of comorbidities, Charlson comorbidity index (CCI), clinical characteristics and the levels of plasma inflammatory markers 〔interleukin (IL)-6, high sensitivity C-reaction protein (hs-CRP), tumor necrosis factor-α (TNF-α), IL-8〕 were studied. Results The top five comorbidities were hypertension, metabolic syndrome and diabetes osteoporosis, bronchiectasis and peripheral vascular diseases. The level of plasma IL-6 was greater in higher CCI score (≥4) group compared with lower CCI score ( P=0.011). Levels of IL-6 and IL-8 and the number of hospitalization in prior year were positively correlated with CCI and age adjusted CCI (r Pr P<0.05). Conclusion Patients with a higher CCI score had more severe symptoms, functional impairment and higher level of inflammatory factors and high frequency of hospital admission due to acute exacerbation. The mechanism by which COPD may play a role in systemic inflammatory response deserves further study.
Keywords: Chronic obstructive pulmonary disease, Comorbidity, Clinical study, Systemic inflammatory response
Full Text:
PDFReferences
VOGELMEIER CF. CRINER GJ, MARTINEZ FJ, et al. Global strategy for the diagnosis* management* and prevention of chronic obstructive lung disease 2017 report. GOLD Executive Summary. Am J Respir Crit Care Med, 2017,195(5):557-582.
ZHONG N, WANG C, YAO W,et al. Prevalence of chronic obstructive pulmonary disease in China:a -large, population- based survey. Am J Respir Crit Care Med, 2007 , 176 ( 11) ; 753-776.
VANFLETEREN LE. SPRUIT MA, GROENEN M. et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2013,187(7);728-735.
SINDEN NJ, STOCK LEY RA. Systemic inflammation and comorbidity in COPD; a result of overspill of inflammatory mediators from the lungs? Review of the evidence. Thorax. 2010,65(10);930-936.
MILLER J, EDWARDS LD, AGUSTi A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med,2013,107(9): 1376-1384.
WANGER J, CLAUSEN LJ, СОАТЕ A, et al. Standardisation of the measurement of lung volumes. Eur Respir J, 2005; 26(3) :511-522.
HUANG WC, WU MF. CHEN HC, et al. Features of COPD patients by comparing CAT with mMRC: a retrospective, cross-sectional study. NPJ Prim Care Respir Med *2015,150(63): 1-7.
CHARLSON ME, CHARLSON RE. PETERSON JC, et al. The Charlson Comorbidity Index isadapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol, 2008,61(12):1234-1240.
JIN JM, YU WL, LI SL, et al. Factors associated with bronchiectasis in patients with moderate-severe chronic obstructive pulmonary disease. Medicine, 2016, 95; 29 (e4219) [2018-09-13]. https://insights, ovid. com./crossref? an = 00005792-201607190-00016. doi: 10. 1097/MD.
Refbacks
- There are currently no refbacks.



